Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Lawrence & Isabel Barnett Drug Development Program Grant

Biogen Idec building

Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

- PMLiVE

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

The neurodegenerative disease affects approximately 30,000 people in the US

- PMLiVE

AI tool better predicts progress of Alzheimer’s versus current clinical tests

The most common form of dementia accounts for up to 80% of all cases

- PMLiVE

Tiziana shares promising results for intranasal foralumab in secondary progressive MS

The neurological disease is estimated to affect 2.8 million people globally

Biogen Idec building

Biogen’s Qalsody granted EC approval to treat rare form of ALS in adults

Mutations in the SOD1 gene are responsible for an estimated 2% of all ALS cases

- PMLiVE

Tiziana shares promising results for intranasal foralumab in multiple sclerosis

The neurological disease affects approximately 2.8 million people worldwide

Biogen Idec building

Biogen’s Qalsody recommended by CHMP to treat rare form of ALS

Mutations in the SOD1 gene are responsible for approximately 2% of all ALS cases

- PMLiVE

Tiziana to develop intranasal foralumab for type 1 diabetes

Approximately 4.7 million people in the UK are currently living with diabetes

- PMLiVE

Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

The neurodegenerative disease affects approximately 27,000 people in the US

Biogen Idec building

Biogen and Alcyone Therapeutics partner in deal worth over $50m

The companies hope to improve treatments for spinal muscular atrophy and amyotrophic lateral sclerosis

- PMLiVE

Tiziana’s foralumab shows continued clinical improvement in secondary progressive MS

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links